Ning et al. (2020) demonstrated experimentally that sitagliptin attenuates DSS-induced experimental colitis, and its effects can be attributed to increased GLP-2 expression and subsequent protection of the intestinal barrier by inhibiting epithelial cell apoptosis and promoting its proliferation. This evidence concerns the gene GCG and colitis.